Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

Animesh D Pardanani, J. Gotlib, A. W. Roberts, M. Wadleigh, S. Sirhan, J. Kawashima, J. A. Maltzman, L. Shao, V. Gupta, Ayalew Tefferi

Research output: Contribution to journalLetter

3 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1034-1037
Number of pages4
JournalLeukemia
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Primary Myelofibrosis
Safety
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. / Pardanani, Animesh D; Gotlib, J.; Roberts, A. W.; Wadleigh, M.; Sirhan, S.; Kawashima, J.; Maltzman, J. A.; Shao, L.; Gupta, V.; Tefferi, Ayalew.

In: Leukemia, Vol. 32, No. 4, 01.04.2018, p. 1034-1037.

Research output: Contribution to journalLetter

Pardanani, AD, Gotlib, J, Roberts, AW, Wadleigh, M, Sirhan, S, Kawashima, J, Maltzman, JA, Shao, L, Gupta, V & Tefferi, A 2018, 'Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis', Leukemia, vol. 32, no. 4, pp. 1034-1037. https://doi.org/10.1038/leu.2017.330
Pardanani, Animesh D ; Gotlib, J. ; Roberts, A. W. ; Wadleigh, M. ; Sirhan, S. ; Kawashima, J. ; Maltzman, J. A. ; Shao, L. ; Gupta, V. ; Tefferi, Ayalew. / Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. In: Leukemia. 2018 ; Vol. 32, No. 4. pp. 1034-1037.
@article{3748694569e049f2a2a95700e914a2f7,
title = "Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis",
author = "Pardanani, {Animesh D} and J. Gotlib and Roberts, {A. W.} and M. Wadleigh and S. Sirhan and J. Kawashima and Maltzman, {J. A.} and L. Shao and V. Gupta and Ayalew Tefferi",
year = "2018",
month = "4",
day = "1",
doi = "10.1038/leu.2017.330",
language = "English (US)",
volume = "32",
pages = "1034--1037",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

AU - Pardanani, Animesh D

AU - Gotlib, J.

AU - Roberts, A. W.

AU - Wadleigh, M.

AU - Sirhan, S.

AU - Kawashima, J.

AU - Maltzman, J. A.

AU - Shao, L.

AU - Gupta, V.

AU - Tefferi, Ayalew

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85044658778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044658778&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.330

DO - 10.1038/leu.2017.330

M3 - Letter

VL - 32

SP - 1034

EP - 1037

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -